Overcoming Rejection: Cellular Delivery for Type 1 Diabetes
16 November 2016 12:00 to 13:00 EST
220 Mass. Avenue, Cambridge MA - USA
Speaker: Arturo J. Vegas Peter Paul Career Development Professor Department of Chemistry Boston University
Seminar Abstract: Type 1 diabetes is a disease characterized by the inability of patients to produce their own insulin hormone and currently afflicts an estimated three million Americans. While a rigorous regimen of blood glucose monitoring coupled with daily injections of insulin remains the leading treatment, diabetics still suffer ill effects due to challenges with daily compliance and imperfect blood glucose control. Recent progress to overcome these challenges will be presented that include the production of mature insulin-producing cells from human stem cells and new materials that can be used to prevent the rejection of transplanted insulin-producing tissue. These technologies are bringing us closer than ever to mitigating this disease and improving the quality of life for these patients.
Entry instructions: There is no cost to attend the seminar. If you are interested in attending please contact Meghan Spencer. Please check in with security at the Novartis visitor's entrance of 220 Massachusetts Avenue and you will be directed to the location of the seminar.
Speaker | Dr. Arturo J. Vegas
Dr. Arturo J. Vegas is the Peter Paul Career Development Professor at Boston University. He is appointed in the Department of Chemistry, has an affiliation with the Department of Biomedical Engineering, and is a core faculty member of both the BU Center for Molecular Discovery as well as the BU Nanotechnology Innovation Center. He was recently awarded a New Innovator Type 1 Diabetes Pathfinder Award by the NIH.
Arturo's lab integrates expertise from the areas of organic synthesis, chemical biology, materials science, and biomedical engineering to address challenging problems in drug delivery. The lab is developing novel chemical tools, materials and approaches for targeting therapeutics to diseased tissues and enabling new medical technologies, with therapeutic emphasis on cancer and diabetes. Current areas of focus are immunomodulation of type 1 diabetes, targeting of tumor microenvironments, and the development of new materials with designed and predictable biological properties.
Arturo received his BA in Biology from Cornell University and a PhD in Chemistry from Harvard University. His doctoral studies under the direction of Professor Stuart Schreiber at Harvard focused on developing novel drug-like compounds that modulate chromatin-modifying enzymes, now popular targets for cancer therapeutics. His postdoctoral work with Professors Robert Langer and Daniel G. Anderson at MIT led to the development of new materials for cell encapsulation, cell-based therapies, and nucleic acid delivery. His work has been published in multiple high-impact journals, including Nature Biotechnology and Nature Medicine, and has led to 10 patents both issued and pending.